Nuclide · weekly issue

Nuclide weekly, 2026-09-28

5 changelog entries, 1 upcoming date. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

What changed in release 0.1.0 (2026-09-22)

New pages, new data and fixes, from the changelog.

Nuclide forked from OnCo, an oncology knowledge graph, and re-scoped to radiopharmaceuticals: therapy (radioligand therapy, targeted alpha therapy, PRRT, radioiodine, radioembolisation, bone-targeted) and diagnostics (PET and SPECT tracers, across oncology, neurology, cardiology, infection and endocrine disease).
Engine changes: added a first-class isotope kind (route /isotopes/); renamed OnCo's cancer kind to indication (route /indications/); the drug kind now covers therapeutic agents and diagnostic tracers together, labelled "Agents".
Carried over 530 records from OnCo's corpus (agents, trials, targets, institutions, people, papers and related records that are relevant to radiopharmaceuticals) and re-scoped them for the new domain. Each carried file keeps a header crediting OnCo; the data licence (CC BY-NC 4.0) follows the records.
Wrote roughly 280 new records: every isotope, the physics and radiochemistry glossary, supply-chain bottlenecks, non-oncology indications, diagnostic tracers, and the fronts and roadmaps of the field.
Removed oncology-only surfaces that do not transfer to this scope, rather than half-porting them: chemotherapy regimens, staging, immune-related adverse events, side-effect and symptom lookups, survivorship, hair loss, tumour boards, the biomarker matrix, patient navigator, prep packs, second opinions, complementary medicine, incidence maps, the "for me" personalisation, coverage/HTA of cancer drugs, and the completeness dashboard.

Upcoming readouts and decisions, next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-10-17 · EANM'26, 39th Annual Congress of the European Association of Nuclear Medicine, Vienna (17 to 21 October) (confirmed) · European Association of Nuclear Medicine, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 radioligand therapy, Radioligand dosimetry · source